Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obefazimod in Moderately to Severely Active Crohn's Disease
NCT06456593Phase 2Recruiting
- Sponsor
- Abivax
- Start
- Oct 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 2 trial of obefazimod in Crohn's disease, sponsored by Abivax. Started Oct 2024; status: recruiting.
02
Drugs
obefazimod
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT06456593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06456593.